Filing Details

Accession Number:
0001638599-16-000970
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-01 16:24:06
Reporting Period:
2016-05-27
Filing Date:
2016-06-01
Accepted Time:
2016-06-01 16:24:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1410098 Cormedix Inc. CRMD () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1313149 W Steven Lefkowitz C/O Cormedix Inc.
1430 Us Highway 206, Suite 200
Bedminster NJ 07921
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Disposition 2016-05-27 7,800 $3.04 159,599 No 4 S Direct
Common Stock, $0.001 Par Value Per Share Disposition 2016-05-31 42,200 $2.85 117,399 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share 174,741 Indirect Wade Capital Corporation Money Purchase Plan
Common Stock, $0.001 Par Value Per Share 10,000 Indirect Reporting Person's Wife
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $2.02 2024-01-09 200,000 200,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $2.02 2024-01-09 30,000 30,000 Direct
Common Stock, $0.001 Par Value Per Share Swries C-3 Non-Voting Convertible Preferred Stock $1.00 45,000 4,500 Direct
Common Stock, $0.001 Par Value Per Share Warrant (right to purchase Common Stock) $0.90 2015-01-08 2020-01-08 22,500 22,500 Direct
Common Stock, $0.001 Par Value Per Share Series C-3 Non-Voting Convertible Preferred Stock $1.00 30,000 3,000 Indirect
Common Stock, $0.001 Par Value Per Share Warrant (right to purchase Common Stock) $0.90 2015-01-08 2020-01-08 15,000 15,000 Indirect
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.90 2023-03-20 120,000 120,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.68 2022-12-05 150,000 100,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $1.10 2021-08-11 30,000 30,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $5.62 2025-03-01 50,000 50,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $1.91 2017-09-20 75,000 75,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-01-09 200,000 200,000 Direct
2024-01-09 30,000 30,000 Direct
45,000 4,500 Direct
2020-01-08 22,500 22,500 Direct
30,000 3,000 Indirect
2020-01-08 15,000 15,000 Indirect
2023-03-20 120,000 120,000 Direct
2022-12-05 150,000 100,000 Direct
2021-08-11 30,000 30,000 Direct
2025-03-01 50,000 50,000 Direct
2017-09-20 75,000 75,000 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.08, inclusive.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.88, inclusive.
  3. The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
  4. The options vested 100% on January 10, 2014.
  5. The options vest in full on the first anniversary of the date of grant.
  6. On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
  7. On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
  8. These options vest quarterly over two years beginning June 13, 2013.
  9. These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
  10. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.